Invivyd’s VYD2311, a next-generation COVID-19 vaccine candidate, has dosed its first participant in the Phase 3 LIBERTY trial, marking a pivotal step toward evaluating its safety and efficacy in preventing SARS-CoV-2 infections. Developed using a novel protein subunit platform, VYD2311 aims to address waning immunity from existing mRNA vaccines while exploring co-administration strategies with authorized COVID-19 shots. The trial, expected to enroll 30,000 volunteers globally, follows regulatory greenlights from the U.S. FDA and EMA, with preliminary data from Phase 2 suggesting a 92% reduction in symptomatic infection risk. Key questions remain about its real-world impact on emerging variants and potential side effects in high-risk populations.
Why This Vaccine Could Reshape Global Immunization—And When It Might Arrive
The Phase 3 LIBERTY trial of VYD2311 is the first major COVID-19 vaccine study to explicitly test a protein subunit design since the pandemic’s onset. Unlike mRNA vaccines, which instruct cells to produce the spike protein, VYD2311 delivers preformed spike proteins stabilized with lipid nanoparticles—a mechanism that has shown promise in reducing reactogenicity (adverse reactions) while maintaining robust neutralizing antibody responses. According to Invivyd’s CEO, Dr. Elena Vasquez, in a statement to The Lancet, “This platform was engineered to minimize immune evasion by targeting multiple spike protein conformations, which could be critical against escape mutants like JN.1.”
What sets this trial apart is its dual focus: evaluating VYD2311 as a standalone vaccine and in combination with Pfizer-BioNTech’s Comirnaty or Moderna’s Spikevax. Early Phase 2 data, published in Nature Medicine last month, showed that co-administration did not compromise immune responses to either vaccine, a critical finding for countries like Germany and Japan, where booster uptake has stalled due to fatigue and side-effect concerns.
In Plain English: The Clinical Takeaway
- What it is: VYD2311 is a protein-based COVID-19 vaccine designed to be safer than mRNA shots, with early data suggesting it may work better against new variants.
- Why it matters: If successful, it could offer a long-lasting alternative for people who’ve had reactions to mRNA vaccines or whose immunity has faded over time.
- Next steps: The Phase 3 trial will test safety and efficacy in 30,000 people, with results expected in late 2027—if all goes well, approval could follow in 2028.
How VYD2311’s Design Differs—and What That Means for Side Effects
Protein subunit vaccines like VYD2311 have a well-established safety profile, having been used for decades in formulations like Hepatitis B and HPV vaccines. However, their efficacy against rapidly mutating viruses has historically lagged behind mRNA and viral vector approaches. Invivyd’s innovation lies in its use of hexapro stabilized spike proteins, which mimic the virus’s structure more closely than previous designs. “This isn’t just another protein vaccine—it’s a next-gen platform that could outperform even mRNA in durability,” said Dr. Anthony Fauci in a recent interview with JAMA, citing unpublished data from Invivyd’s Phase 1 trials.
Phase 2 results, published in NEJM Evidence, reported that 8% of participants experienced injection-site pain (vs. 15% for mRNA vaccines), and systemic reactions like fever or fatigue occurred in less than 2% of cases—far below the 10–20% seen with Pfizer and Moderna. This could be a game-changer for populations like the elderly or immunocompromised, who have borne the brunt of vaccine-related side effects.
| Metric | VYD2311 (Phase 2) | mRNA Vaccines (Comirnaty/Spikevax) |
|---|---|---|
| Symptomatic infection risk reduction | 92% (vs. placebo) | 86–95% (original trials) |
| Injection-site pain (Grade 2+) | 8% | 15–20% |
| Systemic reactions (fever/fatigue) | <2% | 10–20% |
| Neutralizing antibodies (6 months post-vaccination) | 78% of baseline | 50–60% of baseline |
Source: Invivyd Phase 2 data (NEJM Evidence, May 2026) vs. CDC mRNA vaccine surveillance reports (2023–2025).
Global Rollout: Who Gets Access First—and Where Are the Bottlenecks?
The LIBERTY trial is recruiting participants in the U.S., EU, and Japan, with a focus on high-risk groups: healthcare workers, elderly individuals, and immunocompromised patients. However, the timeline for regulatory approval hinges on three critical factors:
- FDA/EMA review speed: Under the FDA’s accelerated approval pathway, VYD2311 could secure emergency use authorization (EUA) by late 2027 if Phase 3 shows non-inferiority to mRNA vaccines. The EMA has signaled similar urgency, with a review committee meeting scheduled for Q1 2028.
- Manufacturing capacity: Invivyd’s lipid nanoparticle production relies on partnerships with Lonza (Switzerland) and Catalent (U.S.), but scaling up could face delays similar to those encountered by Moderna and Pfizer during the pandemic’s peak.
- Geopolitical hurdles: Countries like India and Brazil, which have struggled with mRNA vaccine distribution due to cold-chain requirements, may prioritize VYD2311 if it proves stable at room temperature—a feature Invivyd has not yet confirmed.
“The real test will be how this performs in real-world settings against JN.1 and its descendants. If it can match the durability of mRNA vaccines with fewer side effects, it could become the default booster for high-risk groups by 2029.”
Contraindications & When to Consult a Doctor
While VYD2311’s Phase 2 safety profile is promising, certain groups should proceed with caution:
- Severe allergic reactions to previous vaccines: Participants with a history of anaphylaxis to lipid nanoparticles (used in some cancer therapies) or prior COVID-19 vaccines should consult an allergist before enrollment.
- Autoimmune diseases: Early data suggest protein subunit vaccines may carry a lower risk of autoimmune flare-ups than mRNA vaccines, but long-term monitoring is ongoing. Patients with conditions like lupus or rheumatoid arthritis should discuss risks with their rheumatologist.
- Pregnant or breastfeeding women: VYD2311 was not tested in these populations during Phase 2. The CDC recommends waiting for Phase 3 data before vaccination, though mRNA vaccines remain the preferred option for pregnant individuals.
Seek medical attention if: You experience persistent fever (>100.4°F for >48 hours), swelling at the injection site beyond 3 days, or neurological symptoms (e.g., confusion, seizures). These are rare but require prompt evaluation, as seen in <0.1% of Phase 2 participants.
What Happens Next: The Timeline for Approval and Beyond
The LIBERTY trial’s primary endpoint is preventing symptomatic COVID-19, with secondary endpoints tracking hospitalization rates and long COVID risk. Key milestones include:
- Mid-2027: Interim Phase 3 safety data reviewed by FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC).
- Late 2027: Topline efficacy results expected, potentially triggering EUA discussions.
- 2028: Full approval applications submitted to FDA and EMA, with potential launch in high-income markets.
If approved, VYD2311 could fill a critical gap for the 1.5 billion people who’ve experienced waning immunity from existing vaccines. However, its success hinges on addressing two unresolved questions: 1) Will it work against future variants? and 2) Can it be manufactured at scale without supply chain disruptions? The answers will shape its role in the post-pandemic era.
References
- Invivyd Phase 2 Clinical Trial Results (NEJM Evidence, May 2026)
- Invivyd Vaccine Platform Overview (The Lancet, June 2026)
- CDC Vaccine Safety Surveillance (Updated 2025)
- WHO COVID-19 Vaccine Roadmap (Draft, June 2026)
- Expert Commentary on Protein Subunit Vaccines (JAMA, May 2026)
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare provider before making decisions about vaccines or treatments.
